SHENZHEN and SHANGHAI, August 6, 2020 /PRNewswire/ -- ImmVira Group Company and Shanghai Pharmaceuticals Holding Co., Ltd today announced a clinical collaboration and exclusive license agreement for ImmVira's MVR-T3011 intratumoral oncolytic virus program for the commercialization of novel immunotherapies to treat solid malignant tumors.
Shanghai Pharmaceuticals Holding Co., Ltd. (Shanghai Pharma) (Hong Kong Stock Exchange: 2607) (Shanghai Stock Exchange: 601607) has launched a new stock incentive plan (the Plan) aligned with international standards aimed at retaining and attracting talent while propelling the Chinese healthcare conglomerate into a world-class pharmaceutical innovator.
Takeda eyes $3B from emerging-market asset cull
Bracco Imaging S.p.A., a global leader in diagnostic imaging, and Shanghai Pharmaceuticals Holding Co. Ltd., a leading pharmaceutical group in China - focused on providing innovative drugs in the field of oncology, infectious and cardiovascular diseases - have signed a collaboration agreement on new R&D activities in China.
Let the restructuring of Takeda begin now. The Japanese pharma company is selling off its end of a Chinese marketing and R&D joint venture for $280 million. That’s not much cash for Takeda right now, which is taking on a heavy debt load as it pushes ahead with plans to buy Shire for $62 billion.
A multi-billion dollar Chinese pharma conglomerate, blessed with municipal government backing, is spreading its wings to the US and Europe with eyes on R&D, manufacturing and distribution.
China’s Shanghai Pharma is planning to open an R&D unit in San Diego as part of an international expansion drive that could also include acquisitions in the U.S. and Europe, according to media reports.
Shanghai Pharmaceuticals Holding Co. is exploring further acquisitions after it beat out global buyout firms to buy Cardinal Health Inc.’s Chinese distribution business in a $1.2 billion deal.
Shanghai Pharmaceuticals Holding Co., Ltd., a Chinese pharmaceutical manufacturer and healthcare services provider, has agreed to acquire New York Stock Exchange-listed healthcare services firm Cardinal Health’s China business for US$1.2 billion.